Home

NFLIS-Drug

1.3 million drug reports in 2020

Established in 1997, the National Forensic Laboratory Information System (NFLIS) is a program of the Drug Enforcement Administration (DEA), Diversion Control Division. The DEA's NFLIS-Drug data collection systematically collects drug identification results and associated information from drug cases submitted to and analyzed by participating Federal, State, and local forensic laboratories with drug chemistry sections. The 2020 NFLIS-Drug Annual Report showed that a total of 1,283,971 drug reports were identified by State and local forensic laboratories in the United States.
Learn More
NFLIS-TOX

About 28 million toxicology requests were referred to responding toxicology laboratories in 2019

Toxicology laboratories are a vital source for identifying drugs used by the public. Data from toxicology laboratories can serve as an early warning system to alert the public health community and law enforcement of the drugs they may encounter, leading to improved treatment, prevention, and enforcement policies. The addition of toxicology data to NFLIS is vital for helping DEA improve drug scheduling, enhance available drug intelligence, and better engage their public health partners.
Learn More
NFLIS-MEC

About 500,000 human death cases were accepted by Medical/Coroner offices in 2016

Medical Examiner and coroner offices (MECs) are an important data resource for identifying drugs that are used by the public and are potentially deadly. The addition of NFLIS-MEC will help DEA improve drug scheduling, enhance available drug intelligence, and better engage their public safety and public health partners.
Learn More

Overview Publications FAQs Contact Us

Join NFLIS

Laboratory workers looking at NFLIS website on a laptop

Forensic Laboratories

Toxicology Laboratories

Medical Examiners and Coroners Offices

DEA Diversion Website Synth-Opioid Network Data Query System Overview NFLIS Substances

NFLIS News

NFLIS-Drug Snapshot (December 2022)

Medetomidine continues its upward trend. Eight new substances that were reported across the South, Midwest, and Northeast between October 1 and December 31, 2022 are highlighted in this snapshot. Get the snapshot.
NFLIS-Drug 2021 Annual Report

Between 2020 and 2021, national reports of fentanyl and tramadol increased significantly, while reports of alprazolam, oxycodone, buprenorphine, and amphetamine decreased significantly.

Get the report.
2021 Toxicology Laboratory Survey Report

Among responding toxicology laboratories, 48% used a reference laboratory, 29% served as a reference laboratory, and 23% responded that they did not use or serve as a reference laboratory for toxicology testing. Get the report.
2021 Synth-Opioids Annual Report

The NFLIS DEA Synth-Opioids forum welcomed 307 new members in 2021. Get the report.
NFLIS-Drug Special Report: Gabapentin and Pregabalin Reported in NFLIS, 2011–2020

Gabapentin and pregabalin are prescription drugs that have been approved by the U.S. Food and Drug Administration. From 2011 to 2019, estimated annual gabapentin and pregabalin reports in NFLIS-Drug increased 242% and 18%, respectively. From 2019 to 2020, gabapentin and pregabalin reports decreased 7% and 28%, respectively.

Get the report.